30 results about "Fibronectin type III domain" patented technology

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Provided herein are fusion proteins including at least one binding polypeptide and at least one unstructured polypeptide. The fusion protein may further include at least one linker. Further provided are methods for determining the presence of a target in a sample, methods of treating a disease, methods of diagnosing a disease in a subject, and methods of determining the effectiveness of a treatment for a disease in a subject. The methods may include administering to the subject an effective amount of the fusion protein.

The invention discloses cysteine engineered monospecific and bispecific EGFR and / or c-Met FN 3 domain containing molecules comprising one or more free cysteine amino acids. The molecules are prepared by mutagenizig a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules: and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

Monospecific and bispecific EGFR and / or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

The invention provides a plasmid comprising two or more anti-obesity genes. Also provided by the invention are compositions and host cells comprising the plasmid and methods of increasing the metabolic activity in a mammal. The invention provides a plasmid comprising two or more of (a) a nucleic acid sequence encoding islet amyloid polypeptide (IAPP), (b) a nucleic acid sequence encoding leptin (LEP), and (c) a nucleic acid sequence encoding fibronectin type III domain containing 5 (FNDC5).

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Cysteine engineered monospecific and bispecific EGFR and / or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequenceof a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule, isolated cysteine engineered monospecific or bispecific FN3 domain containing moleculesmay be covalently attached to a detection label or a drug moiety and used therapeutically.

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Fibronectin type III domain (FN3) specifically binding to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing FN3 domains, and related vectors, and detectably labeled FN3 domains Can be used in therapeutic and diagnostic applications.

The invention belongs to the field of biotechnologies, and relates to a method for building efficient N-glycosylation receptor protein models in Escherichia coli by the aid of skeleton proteins Fn3 (fibronectin type III domain). The human-derived proteins Fn3 with N-glycosylation recognition sites are used as receptor proteins. The method includes steps constructing Fn3-Gly recombinant protein gene expression vectors; forming recombinant genes of the N-glycosylation recognition sites carried by the human-derived proteins Fn3; cloning the genes onto the expression vectors capable of secreting the recombinant genes onto pericoel. Recombinant proteins expressed by the vectors can be used as the prokaryote research N-glycosylation receptor protein models for N-glycosylation recombinant research. The method has the advantages that the nearly 100% N-glycosylation recombinant proteins which are good in heat stability, high in expression quantity and convenient to separate and purify can be obtain, excellent protein receptors can be provided for N-glycosylation recombinant engineering, the receptor protein models can be provided for prokaryote N-glycosylation recombinant engineering, and foundation can be laid for efficiently carrying out oligosaccharide chain analysis and function research in late periods of the N-glycosylation recombinant engineering.

The invention belongs to the field of biotechnologies, and relates to a method for applying recombinant expression separated and purified human-derived protein Fn3 (fibronectin type III domain) mutants as N-glycosylation efficiency detection model proteins. The method includes steps of constructing Fn3-Gly-loop recombinant protein gene expression vectors of the Fn3 mutants; jointly transforming the constructed expression vectors into Escherichia coli engineering strains CLM37 by means of electric shock processes; screening the expression vectors by the aid of antibiotics to obtain positive clones. Recombinant proteins contain Fn3-Gly-loop proteins which are about to be modified by recombinant glycosyl, and the Fn3-Gly-loop fusion protein glycosylation efficiency can be detected by the aid of Western Blot processes. The method has the advantages that the skeleton proteins Fn3 in Escherichia coli are used as receptor proteins, accordingly, the model receptor proteins suitable for N-glycosylation modification efficiency research can be constructed, and the recombinant protein glycosylation efficiency can be easily, quickly and efficiently detected in the Escherichia coli.

BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.